Neurocrine Biosciences Inc (NBIX) stock
NBIXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/307% below fair value
$165.31−2.09 (-1.25%)
Close on Nov 16, 2026Market cap $16.80BP/E 24.2Yield –
Neurocrine Biosciences cash
Cash and short-term investments held at the end of each period.
Neurocrine Biosciences's cash was $389.80M at Jun 30, 2026. For fiscal 2025 it was $1.48B, up 36.6% from the year before. Over ten years it grew 34.1% a year on average. The highest annual figure on record is $1.48B in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | +36.6% |
| FY2024 | Dec 31, 2024 | $1.08B | +4.3% |
| FY2023 | Dec 31, 2023 | $1.04B | +4.3% |
| FY2022 | Dec 31, 2022 | $997.10M | +39.6% |
| FY2021 | Dec 31, 2021 | $714.50M | -11.2% |
| FY2020 | Dec 31, 2020 | $804.20M | +19.4% |
| FY2019 | Dec 31, 2019 | $673.70M | +2.6% |
| FY2018 | Dec 31, 2018 | $656.40M | +26.1% |
| FY2017 | Dec 31, 2017 | $520.42M | +490.4% |
| FY2016 | Dec 31, 2016 | $88.15M | +11.6% |
| FY2015 | Dec 31, 2015 | $78.99M | -59.2% |
| FY2014 | Dec 31, 2014 | $193.81M | +33.0% |
| FY2013 | Dec 31, 2013 | $145.74M | -15.8% |
| FY2012 | Dec 31, 2012 | $173.01M | +34.0% |
| FY2011 | Dec 31, 2011 | $129.10M | +1.8% |
| FY2010 | Dec 31, 2010 | $126.87M | +239.9% |
| FY2009 | Dec 31, 2009 | $37.33M | -45.5% |
| FY2008 | Dec 31, 2008 | $68.47M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $389.80M | -60.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.32B | +39.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.48B | +36.6% |
| Q3 FY2025 | Sep 30, 2025 | $1.11B | -9.2% |
| Q2 FY2025 | Jun 30, 2025 | $975.60M | -6.1% |
| Q1 FY2025 | Mar 31, 2025 | $943.50M | -22.1% |
| Q4 FY2024 | Dec 31, 2024 | $1.08B | +4.3% |
| Q3 FY2024 | Sep 30, 2024 | $1.23B | +12.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.04B | +6.4% |
| Q1 FY2024 | Mar 31, 2024 | $1.21B | +35.3% |
| Q4 FY2023 | Dec 31, 2023 | $1.04B | +4.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.10B | +37.0% |
| Q2 FY2023 | Jun 30, 2023 | $976.70M | +50.7% |
| Q1 FY2023 | Mar 31, 2023 | $894.60M | +34.5% |
| Q4 FY2022 | Dec 31, 2022 | $997.10M | +39.6% |
| Q3 FY2022 | Sep 30, 2022 | $799.40M | +4.4% |
| Q2 FY2022 | Jun 30, 2022 | $648.30M | -26.7% |
| Q1 FY2022 | Mar 31, 2022 | $664.90M | -23.9% |
| Q4 FY2021 | Dec 31, 2021 | $714.50M | -11.2% |
| Q3 FY2021 | Sep 30, 2021 | $765.90M | -18.9% |
| Q2 FY2021 | Jun 30, 2021 | $884.90M | -6.7% |
| Q1 FY2021 | Mar 31, 2021 | $873.70M | +13.2% |
| Q4 FY2020 | Dec 31, 2020 | $804.20M | +19.4% |
| Q3 FY2020 | Sep 30, 2020 | $944.70M | +39.9% |
| Q2 FY2020 | Jun 30, 2020 | $948.30M | +51.6% |
| Q1 FY2020 | Mar 31, 2020 | $771.70M | +45.7% |
| Q4 FY2019 | Dec 31, 2019 | $673.70M | +2.6% |
| Q3 FY2019 | Sep 30, 2019 | $675.33M | +235.6% |
| Q2 FY2019 | Jun 30, 2019 | $625.49M | +263.9% |
| Q1 FY2019 | Mar 31, 2019 | $529.59M | +194.5% |
| Q4 FY2018 | Dec 31, 2018 | $656.40M | +26.1% |
| Q3 FY2018 | Sep 30, 2018 | $201.21M | -26.1% |
| Q2 FY2018 | Jun 30, 2018 | $171.90M | -45.3% |
| Q1 FY2018 | Mar 31, 2018 | $179.81M | +160.0% |
| Q4 FY2017 | Dec 31, 2017 | $520.42M | +490.4% |
| Q3 FY2017 | Sep 30, 2017 | $272.43M | +173.1% |
| Q2 FY2017 | Jun 30, 2017 | $314.11M | – |
| Q1 FY2017 | Mar 31, 2017 | $69.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $88.15M | – |
| Q3 FY2016 | Sep 30, 2016 | $99.76M | – |
See a number that looks wrong?